Arry Dieudonne

I have been at New Jersey Medical School/Rutgers (formerly University of Medicine and Dentistry of New Jersey) since 1992, first as a fellow in the well-known Oleske group and then as a faculty member in the Department of Pediatrics (1994-ongoing). Since then, Pediatric HIV infection/AIDS has been my professional focus and passion. Currently, my clinical activities encompass not only the University Hospital but also Newark Beth Israel Medical Center and Cooperman-Saint Barnabas Medical Center. My early encounter with HIV/AIDS in children, a devastating and fatal condition, made me realize the urgent need for further studies to answer many perplexing questions, acquire novel medical knowledge, develop diagnostic methods, and discover new therapies. Consequently, I have participated in over 70 cohort studies to better understand the disease process and improve the outcomes of HIV infection in children. These investigations, which are still ongoing, involved collaborations between many academic centers including UMDNJ/Rutgers. The outcomes of these pioneering studies have been highly successful, enlightening and gratifying. I have witnessed and participated in the development and implementation of Protocol 076, the master protocol that has revolutionized the prevention of HIV transmission from mother to infant. Throughout my medical career, I have collaborated with many universities all over the world to develop treatment protocols through Pediatric AIDS Clinical Trials (PPACTG), IMPAACT. I served as the Pediatric Director for the NJMS Clinical Trial Unit (CTU) and was responsible for the health care team that provided care to a cohort of HIV-infected children and youth. I was also the Principal Investigator at our site for Longitudinal Epidemiologic Study to Gain Insight into HIV/AIDS in children and Youth (LEGACY), a multi-center CDC funded project. Since 2008, I have been the Principal Investigator of the Pediatric HIV/AIDS Cohort Study (PHACS), a NIH /NICHD funded grant through Harvard School of Public Health, which has 2 components, Surveillance Monitoring of Antiretroviral Treatment and Toxicities (SMARTT), monitoring HIV exposed infants born to HIV-infected mothers, and Adolescent Master Protocol (AMP), following perinatally infected adolescents and young adults. Being a consistent contributor to the global effort for the development of treatments to eradicate HIV/AIDS in children has been extremely